Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.

Authors :: Kazda CM
Ding Y
Kelly RP
Garhyan P
Shi C
Lim CN
Fu H
Watson DE
Lewin AJ
Landschulz WH
Deeg MA
Moller DE
Hardy TA
Source :: Diabetes care [Diabetes Care] 2016 Nov; Vol. 39 (11), pp. e199-e200.
Publication Year :: 2016

Subjects :: Biphenyl Compounds
Glucagon
Humans
Diabetes Mellitus, Type 2
Receptors, Glucagon antagonists & inhibitors

Full Text Access

Tools